Company Tekmira Pharmaceuticals Corporation Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 50 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | 53 | 17-03-31 |
Michael Sofia
CTO | Chief Tech/Sci/R&D Officer | 66 | 15-02-28 |
John Naftzger
CMP | Compliance Officer | 57 | 23-07-09 |
Investor Relations Contact | - | 21-09-20 | |
Shannon Briscoe
HRO | Human Resources Officer | - | 21-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 59 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
Keith Manchester
BRD | Director/Board Member | 55 | 15-03-03 |
Frank Torti
CHM | Chairman | 45 | 18-11-25 |
Chief Executive Officer | 50 | 14-06-30 | |
Director/Board Member | 54 | 23-07-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 188,717,409 | 146,657,129 ( 77.71 %) | 0 | 77.71 % |
Company contact information
![address Tekmira Pharmaceuticals Corporation(TKM)](https://cdn.zonebourse.com/static/address/1411938.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+5.37% | 97.06B | |
+7.24% | 41.54B | |
-8.49% | 33.89B | |
+83.27% | 29.78B | |
-12.97% | 15.63B | |
-0.80% | 13.66B | |
-12.22% | 11.43B | |
+173.60% | 10.37B | |
+4.64% | 9.14B |